Dr. Richard Gordon Presents on RRx-001 at MDS Annual Conference in Philadelphia, PA

Sep 30, 2024

It was no “Rocky” start for Associate Professor, Dr. Richard Gordon from Queensland, Australia, at the 2024 International Parkinson and Movement Disorder Society (MDS) Conference in Philadelphia, Pennsylvania. He delivered a well-attended oral presentation on the activity of the multimechanistic small molecule, RRx-001 (nibrozetone), in Parkinson’s Disease.

Like the Liberty Bell, an iconic symbol of American independence, Dr. Gordon stands for freedom — freedom from the tyranny of neurodegenerative diseases like Parkinson’s and others that have ruled over humanity throughout history.

Dr. Gordon hopes to make history with his research on RRx-001, which, Liberty Bell pun fully intended, may finally crack the code on how to slow, stop or reverse Parkinson’s Disease and other neurodegenerative diseases. RRx-001 is neuroprotective and potentially disease-modifying, meaning that it has been used in Dr. Gordon’s lab and elsewhere to prevent and mitigate neurological damage. It is also well tolerated, having been safely evaluated in 400+ patients without any dose limiting toxicities or related serious adverse events.

Next up for Dr. Gordon on his whistlestop tour of the United States is the Society for Neuroscience (SfN) conference in Chicago where he will give a featured oral presentation on the disease-modifying activity of RRx-001 in the fatal neurodegenerative disease, ALS/MND. Stay tuned for our post-presentation SfN roundup on October 9th.